IBS IBS. irritable bowel syndrome IBS IBS. in situ. E -hydroxy-l-tryptophan. -dihydroxy- -hexadien IBS IBS IBS IBS.

Similar documents
Diagnosis and Treatment of Irritable Bowel Syndrome

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

Alternating bowel pattern: what do people mean?

Why does my stomach hurt? Exploring irritable bowel syndrome

Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome

ICCR rotation February 7, The efficacy, safety and tolerability of tegaserod in celiac disease patients

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey

MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES

ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

Irritable bowel syndrome (IBS) is a

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary

Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment

A Prospective Assessment of Bowel Habit in Irritable Bowel Syndrome in Women: Defining an Alternator

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population

Irritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center

Effect of Itopride Hydrochloride on the Ileal and Colonic Motility in Guinea Pig In Vitro

Antidiarrheals Antidiarrheal

Epidemiology and Impact of IBS

IBS current status Peter Laszlo Lakatos

J Neurogastroenterol Motil, Vol. 16 No. 2 April, 2010 DOI: /jnm Journal of Neurogastroenterology and Motility

What should be the primary end point in irritable bowel syndrome?

T he irritable bowel syndrome (IBS) is a symptom complex


Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)

Emerging Treatments for IBS-C and Clinical Trial Endpoints

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

... SELECTED ABSTRACTS...

International Journal of Pharma and Bio Sciences V1 (2) 2010

Applying Case Definition Criteria to Irritable Bowel Syndrome

Accepted Article. Irritable bowel syndrome (IBS) subtypes: Nothing. Fermín Mearin Manrique. DOI: /reed /2016 Link: PDF

I rritable bowel syndrome (IBS) is a chronic

COMORBIDITY OF IRRITABLE BOWEL SYNDROME, PANIC DISORDER, AND AGORAPHOBIA IN THE GENERAL POPULATION IN JAPAN

Irritable bowel syndrome (IBS) is a ... PRESENTATION... Defining and Diagnosing Irritable Bowel Syndrome

Gastrointestinal Society 2016 SURVEY RESULTS

Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN

Results. Assessment of IBS. Determination of Concordance

Gastrointestinal motility modulating drugs include all compounds which have pharmacological

Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation

Functional bowel disorders and functional abdominal pain

Advancing gastroenterology, improving patient care

Primary Management of Irritable Bowel Syndrome

Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints

Comparing the efficacy of polyethylene glycol. glycol (PEG), magnesium hydroxide, lactulose. treatment of functional constipation in children

Stimulatory Action of Itopride Hydrochloride on Colonic Motor Activity in Vitro and in Vivo

Sohair A Hagag *1, Shereen Eassa 1 and Mahmoud Abdou Aashour 2

REVIEW ARTICLE. Evidence- and Consensus-Based Practice Guidelines for the Diagnosis of Irritable Bowel Syndrome

References. AMITIZA [package insert]. Bethesda, MD: Takeda Pharmaceuticals America., Inc; Takeda Pharmaceuticals America, Inc. Data on File.

Diagnostic value of the Manning criteria in irritable bowel syndrome

Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome

Chronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016

Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment

IBS: overview and assessment of pain outcomes and implications for inclusion criteria

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

Digestion. Text. What You Don t Know Can Hurt You!

Effects of young barley leaf powder on irritable bowel syndrome in rats.

IBS Irritable Bowel syndrome Therapeutics II PHCL 430

WOMEN WITH IRRITABLE BOWEL SYNDROME ACCORDING TO ROME II CRITERIA IN JORDAN

Uncomplicated diverticular disease is not a common cause of colonic symptoms

Irritable Bowel Syndrome and Chronic Constipation

Prevalence and management of abdominal cramping and pain: a multinational survey

Predictors of health care seeking for irritable bowel syndrome: a population based study

JNM Journal of Neurogastroenterology and Motility

The Opportunity: c-ibs and pain relief with confidence YKP10811

Irritable Bowel Syndrome

FOOT OFF THE BRAKES. Kerri Novak MD MSc FRCPC. Chronic Constipation: Taking the Foot off the Brakes Dr. Kerri Novak

This is a repository copy of Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?.

Human Anatomy rectum

Constipation an Old Friend. Presented by Dr. Keith Harris

IBS is associated with an increased incidence of psychological

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

AN EXPERT SYSTEM FOR THE DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

PainReliefSciences.com 1

Effect of Histamine H2-receptor Antagonists on. Acetaminophen and its Metabolites in Human Plasma

Irritable bowel syndrome (IBS) is a classic functional gastrointestinal

Constipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 June 2011

อภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น

Delfini Group, LLC Evidence & Value based Solutions For Health Care Clinical Improvement Consults, Content, Seminars, Training & Tools

IBS - Definition. Chronic functional disorder of GI generally characterized by:

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Chronic constipation affects up to 63

Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders

What is Dietary Fibre?

Pharmacology. Drugs that Affect the Gastrointestinal System

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

The burden and management of patients with IBS: results from a survey in Spanish gastroenterologists

A Review of the Literature on Gender and Age Differences in the Prevalence and Characteristics of Constipation in North America

Systematic review: the effects of fibre in the management of chronic idiopathic constipation

REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

Small-Bowel and colon Transit. Mahsa Sh.Nezami October 2016

Effect of Ginseng Saponins on a Rat Visceral Hypersensitivity Model

Evolving Therapy in Irritable Bowel Syndrome (IBS)

Evidence-based Treatment Strategies for

Epidemiology of Functional Diarrhea and Comparison with Diarrhea-Predominant Irritable Bowel Syndrome: A Population-Based Survey in China

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

Folia Pharmacol. Jpn.119 IBS IBS in situ E -hydroxy-l-tryptophan IBS - - e-mail: yuji.iwanaga@abbott.com IBS 1. irritable bowel syndromeibs -dihydroxy- -hexadien IBS IBS IBS 2. 1

Chemical structure of polycarbophil cal- Fig. 1 cium in vitro ph. Ca in vitro ph Fig. 3 Effect of polycarbophil and CMC-Na on water flux by in situ single pass perfusion method. P.. Reproduced with permission from ref.. Pharm Sci Fig. 2 Effect of ph on equilibrium swelling of polycarbophil. Reproduced with permission from ref.. ph ph ph CMC-Na 2 in situ in situ

Fig. 4 Effects of loperamidea, polycarbophil calciumb, CMC-NaCand trimebutine maleatedon sennoside-induced diarrhea in dogs. P.. Reproduced with permission from ref.. E -hydroxy-l-tryptophan CMC- Na

Table 1 Final global improvement ratings associated with disease statusdiarrheaconstipation Status Dose Total Improvement rate L. Diarrhea M. H. Htest Cochran-Armitage test Multiple comparison More than improved P. L:M P. L:H P. M:H P. P. L. Constipation M H P. L:M P. L:H P. M:H P. P. Dose: L,. gday; M,. gday; H. gday. : Number of remarkably improved cases, :Numberof improved cases, : Number of slightly improved cases, : Number of unchanged cases, : Number of aggravated cases. means statistically significancep.. statistic significance level in multiple comparisonu test: P.. Modified from ref.. IBS 3. C C C C C 4. II IBS.g.g

.g.g..g..g..g.g III IBS g.g.... 5. IBS -HT -HT -HT IBS -HT IBS IBS Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ and Muller-Lissner S: C. Functional bowel disorders and D. Functional abdominal pain. In The Functional Gastrointestinal Disorders, Second Edition, Edited by Drossman DA, Corazziari E, Talley NJ, Thompson WG and Whitehead WE, pp -, Degnon Associates, MacLean Camilleri M and Choi MG: Review article: irritable bowel syndrome. Aliment Pharmacol Ther 11, - Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 120,- Drossman D and Camilleri M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112,- IBS G IRes75,- IBS GIRes75,- Olden KW and Schuster MM: Irritable bowel syndrome. In Sleisenger Fordtran s Gastrointestinal and Liver Disease, PathophysiologyDiagnosis Management, Edited by Feldman M, Scharschmidt BF and Sleisenger MH, Vol 1, pp-, W.B. SAUNDERS COMPANY, Philadelphia Yamada T, Kitayama M, Yamazaki M, Nagata O, Tamai I and Tsuji A: Physicochemical properties of calcium polycarbophil, a water-absorbing polymer. J Pharm Pharmacol 48,- Yamada T, Saito T, Takahara E, Nagata O, Tamai I and Tsuji A: Decalcification of calcium polycarbophil in rats. Biol Pharm Bull 203,- Yamada T, Saito T, Iwanaga Y, Kitayama M, Nagata O, Tamai I and Tsuji A: The effect of polycarbophil on water transport in rat intestine. Pharm Sci 2,- Iwanaga Y, Terasaki T, Tamai I, Yamazaki M, Kato H, Ito Y, Tsuji A and Itoh Z: Effects of polycarbophil on intestinal water flux and defecation. Gastroenterology 1024, Suppl, A Yasumori A, Saito T, Kasakawa E, Mizutani F, Iwanaga Y, Morikawa K, Nagata O and Kato H: Effect of HSR-on intestinal transit in mice and rats. Jpn J Pharmacol 76, Suppl,P Saito T, Yamada T, Iwanaga Y, Morikawa K, Nagata O, Kato H, Mizumoto A and Itoh Z: Calcium polycarbophil, a water absorbing polymer, increases bowel movement and prevents sennosideinduced diarrhea in dogs. Jpn J Pharmacol 83,- Saito T, Yasumori A, Kasakawa E, Mizutani F, Iwanaga Y, Morikawa K, Nagata O and Kato H: A novel constipation model induced by low-fiber diets and the effect of HSR-in rats. Jpn J Pharmacol 76, Suppl,P Polycarbophil calciumhsr- 281,- Naggar VFB and Samaha MW: Adsorption studies of metoclopramide HCl on polycarbophil and preparation of directly compressed zero-order release tablets. Pharm Ind 515,- Polycarbophil calciumhsr- 281,- 316, -

HSR- II 26 Suppl, - HSR- III 26 Suppl,- Gershon MD: Review article: roles played by - hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13, Suppl,- Eglen RM and Hegde SS:-Hydroxytryptamine- HT receptors: physiology, pharmacology and therapeutic potential. Exp Opin Invest Drugs 54, - Horton R: Lotronex and the FDA: a fetal erosion of integrity. Lancet 357,- Prather CM, Camilleri M, Zinsmeister AR, McKinzie S and Thomforde G: Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 118,- De Ponti F and Tonini M: Irritable bowel syndrome, New agents targeting serotonin receptor subtypes. Drugs 613,- AbstractPhysicochemical and pharmacological characteristic and clinical efficacy of an anti-irritable bowel syndrome agent, polycarbophil calciumpolyful. Yuji IWANAGALaboratory of Pharmacology, Research Division, Hokuriku Seiyaku Co., Ltd.,--Inokuchi, Katsuyama City, Fukui-, Japan. Folia Pharmacol. Jpn.Nippon Yakurigaku Zasshi119, Irritable bowel syndromeibsis a functional bowel disorder characterized by abdominal pain or discomfort and abnormal defecation. Polycarbophil calcium, a water-absorbing polymer, is expected to improve stool consistency. Polycarbophil calcium decalcified under the acidic condition and then absorbed times its weight of water under the neutral condition. In in situ experiments using rat jejunum and colon, polycarbophil decreased water absorption by the intestine without affecting water secretion. Polycarbophil inhibited prostaglandin E -,-hydroxy-l-tryptophan- and castor oil-induced diarrhea in mice or rats. Polycarbophil calcium also inhibited sennoside-induced diarrhea in dogs. Polycarbophil increased the weight of feces in naive or low-fiber diet feeding rats. In naive dogs, polycarbophil calcium increased stool frequency, stool weight and moisture. Polycarbophil was not absorbed from the gastrointestine, not metabolized and eliminated into feces in rats and dogs. Polycarbophil calcium did not affect the absorption of coadministered drugs in dogs. In the dose-finding clinical study for IBS, polycarbophil calcium was effective both in diarrhea and constipation. In the Phase III study, polycarbophil calcium was superior to trimebutine maleate in efficacy and equal in safety. Emesisvomiting and thirst were observed, but episodes of diarrhea or constipation by excessive action were few. Polycarbophil calcium seems promising as an anti- IBS agent. Keywords: irritable bowel syndrome; diarrhea; constipation; polycarbophil calcium; water-absorbing polymer Mayo Clinic Sydney F. Phillips